P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL

Podobne knjige/članki

• P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL
  od: P Sonneveld, et al.
  Izdano: (2022-04-01)
• Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
  od: Dong Liang, et al.
  Izdano: (2024-09-01)
• Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma
  od: Meletios A. Dimopoulos, et al.
  Izdano: (2015-01-01)
• Comparison of bortezomib-cyclophosphamide-dexamethasone <em>versus</em> bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
  od: Rafiye Ciftciler, et al.
  Izdano: (2020-05-01)
• Treatment of light chain deposition disease with bortezomib and dexamethasone
  od: Efstathios Kastritis, et al.
  Izdano: (2009-02-01)